Incorporating epilepsy genetics into clinical practice:A 360°evaluation by Oates, Stephanie et al.
Syddansk Universitet
Incorporating epilepsy genetics into clinical practice
A 360°evaluation
Oates, Stephanie; Tang, Shan; Rosch, Richard; Lear, Rosalie; Hughes, Elaine F.; Williams,
Ruth E.; Larsen, Line H.G.; Hao, Qin; Dahl, Hans Atli; Møller, Rikke S; Pal, Deb K.
Published in:
npj Genomic Medicine
DOI:
10.1038/s41525-018-0052-9
Publication date:
2018
Document version
Publisher's PDF, also known as Version of record
Document license
CC BY
Citation for pulished version (APA):
Oates, S., Tang, S., Rosch, R., Lear, R., Hughes, E. F., Williams, R. E., ... Pal, D. K. (2018). Incorporating
epilepsy genetics into clinical practice: A 360°evaluation. npj Genomic Medicine, 3, [13]. DOI: 10.1038/s41525-
018-0052-9
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 12. Jul. 2018
ARTICLE OPEN
Incorporating epilepsy genetics into clinical practice: a 360°
evaluation
Stephanie Oates1,2, Shan Tang3, Richard Rosch1, Rosalie Lear3, Elaine F. Hughes1,2, Ruth E. Williams2, Line H. G. Larsen4, Qin Hao4,
Hans Atli Dahl4, Rikke S. Møller5,6 and Deb K. Pal1,2,3
We evaluated a new epilepsy genetic diagnostic and counseling service covering a UK population of 3.5 million. We calculated
diagnostic yield, estimated clinical impact, and surveyed referring clinicians and families. We costed alternative investigational
pathways for neonatal onset epilepsy. Patients with epilepsy of unknown aetiology onset < 2 years; treatment resistant epilepsy; or
familial epilepsy were referred for counseling and testing. We developed NGS panels, performing clinical interpretation with a
multidisciplinary team. We held an educational workshop for paediatricians and nurses. We sent questionnaires to referring
paediatricians and families. We analysed investigation costs for 16 neonatal epilepsy patients. Of 96 patients, a genetic diagnosis
was made in 34% of patients with seizure onset < 2 years, and 4% > 2 years, with turnaround time of 21 days. Pathogenic variants
were seen in SCN8A, SCN2A, SCN1A, KCNQ2, HNRNPU, GRIN2A, SYNGAP1, STXBP1, STX1B, CDKL5, CHRNA4, PCDH19 and PIGT. Clinician
prediction was poor. Clinicians and families rated the service highly. In neonates, the cost of investigations could be reduced from
£9362 to £2838 by performing gene panel earlier and the median diagnostic delay of 3.43 years reduced to 21 days. Panel testing
for epilepsy has a high yield among children with onset < 2 years, and an appreciable clinical and ﬁnancial impact. Parallel gene
testing supersedes single gene testing in most early onset cases that do not show a clear genotype-phenotype correlation. Clinical
interpretation of laboratory results, and in-depth discussion of implications for patients and their families, necessitate
multidisciplinary input and skilled genetic counseling.
npj Genomic Medicine  (2018) 3:13 ; doi:10.1038/s41525-018-0052-9
INTRODUCTION
Genetic testing and counseling for epilepsy is now being
incorporated into everyday practice in many parts of the
industrialised world.1 This advance has been driven by rapid
discoveries in the aetiology of rare monogenic epilepsies, and
technological developments in next generation resequencing
(NGS).2 The integration of NGS testing into practice is accom-
panied by several challenges including clinician education, results
interpretation, and counseling for patients and their families.3
We reﬂect on our experience of this transformational change
from the perspective of a health service provider, speciﬁcally
assessing: (a) the effectiveness and utility of NGS testing, (b) the
necessary inputs and (c) areas where service improvements can be
made to facilitate the transition to 'Precision' or 'Personalised
Medicine'. We also asked speciﬁc questions about single vs parallel
gene testing pathways based on clinician predictive ability; the
relative diagnostic yield for different age of onset or epilepsy
syndrome; what priorities clinicians and families identify; the
resources necessary to provide an effective service, and whether
NGS can save time and money4,5 using the neonatal epilepsy
group as an example. We address these questions in the context
of a review of the initial operation of a UK regional epilepsy
genetics service to a population of approximately 3.5 million. To
our knowledge there is limited published data from other
specialist epilepsy genetics services that similarly reviews their
own experience,6 therefore this study aims to ﬁll a gap in that
respect. However, there are several articles on the utility of genetic
testing in epilepsy and published yield.2,7–9 Our study aims to add
to the current literature and, in addition, ﬁll in the gaps in
knowledge about how to set up a tailored epilepsy genetics
service, what referring clinicians and patients and families think
about such a service, and the cost saving implications of
performing genetic testing.
RESULTS
Demographics
Ninety-six unrelated eligible patients (55 male) were referred to
the service, either through the specialist outpatient clinic (n= 40)
or directly for molecular investigation through their paediatrician
or paediatric neurologist. All were consented for gene panel
analysis. As this was a new service, many patients were tested
years after onset or diagnosis, including one adult patient and two
post-mortem. We categorized them broadly into age of onset and
syndrome classes (Table 1). Sixty-four percent (49/77) were
classiﬁed as drug-resistant.10
Identiﬁed variants
Seventy-four of our 96 patients had previous array comparative
genomic hybridisation (aCGH) performed (77%), of which 16 (22%)
Received: 6 September 2017 Revised: 4 April 2018 Accepted: 9 April 2018
1King’s College Hospital, London, UK; 2Evelina London Children’s Hospital, London, UK; 3Kings College London, London, UK; 4Amplexa Genetics, Odense, Denmark; 5Danish
National Epilepsy Centre, Dianalund, Denmark and 6Institute for Regional Health research, University of Southern Denmark, Odense, Denmark
Correspondence: Deb K. Pal (deb.pal@kcl.ac.uk)
These authors contributed equally: Stephanie Oates and Shan Tang.
www.nature.com/npjgenmed
Published in partnership with the Center of Excellence in Genomic Medicine Research
had an identiﬁed benign chromosomal rearrangement. The
remainder had no detected rearrangement and a normal
chromosomal complement. Patients with pathological ﬁndings
on the aCGH do not tend to make their way into our clinic. In fact,
only three patients out of forty-four referred for aCGH by one of
the three local clinicians we work with were found to have a
pathogenic chromosomal rearrangement by the local laboratory
(ViaPath) and were not referred on to our service: one showing
Angelman’s syndrome; one Klinefelter’s syndrome; and one
showing 9q34 deletion. However, the match between the epilepsy
phenotype and the chromosomal rearrangement is not conclusive
in any of these three cases so none of these can be considered
completely 'solved'.
For NGS panel testing, 11 patients were tested on the original
Childhood Epilepsy panel containing 45 genes (CHE-45); 11 on the
CHE-76 (Childhood Epilepsy panel containing 76 genes); 49 on
CHE-85 (Childhood Epilepsy panel containing 85 genes), and 23
on CHE-102 (Childhood Epilepsy panel containing 102 genes); 2
patients were referred to the epilepsy genetics service with
existing positive gene panel results from another provider. The
gene panel itself was designed by the following co-authors: RSM,
DKP and HAD. The criteria for including a gene on the panel were
that it should have been reported more than once in patients with
monogenic epilepsies. The selection of genes on the panel was
regularly evaluated and updated. The panel included of targeted
capture of all exons and at least ﬁve base pairs of ﬂanking intronic
sequence of the selected genes.
The overall target coverage of the genes on the Amplexa CHE-
46 panel was 95–97%; hence, 3–5% of the regions were not
analyzed, and some variations may have been missed, while the
average target coverage for the larger three panels was 98–99.5%.
The regions missed were more or less identical across the different
samples, i.e., regions difﬁcult to amplify due to high GC content,
repeat elements, or regions with homology in other parts of the
genome.
Amplexa Genetics reporting follows the ACMG guidelines.
However, there is an argument that these guidelines are not very
suitable for conditions with variable penetrance (which many
types of epilepsy have been shown to have). As our knowledge
and understanding of epilepsy genetics is still limited, they do also
report Class II (benign) variants, and this allows us to monitor
them in case our understanding changes in the future. When we
receive a report from Amplexa, we then compare that with our
understanding of the phenotype to check whether this ﬁts with
the clinical picture. This often leads us to re-grade classiﬁcations of
variants reported. If, however, we are still uncertain, we will
request assistance from experienced colleagues in the ﬁeld.
Parental segregation may also lead to re-classiﬁcation of variant
class if the results ﬁt with the phenotype or family history, e.g.,
95% of SCN1A variants causing SMEI will be de novo. Parental
segregation was deemed necessary when a class IV variant
(deﬁned as per the ACMG 2015 Guidelines11) or above was
identiﬁed in the child, or a Class III variant was identiﬁed and it
was in a gene that seemed to match with the child’s phenotype
and/or family history, or in genes where de novo variants are
usually pathogenic.
61% of patients (n= 59) had one or more variants (single
nucleotide variants only) reported: 31 had only benign variants; 9
had variants of unknown signiﬁcance (VUS), and 19 had variants
judged to be of pathogenic signiﬁcance. The average number of
any variant, not just pathogenic, increased in line with the
expansion in size of the gene panel (CHE-46: 1.3; CHE-102: 1.8)
indicating the additional burden of clinical interpretation.12 We
were constrained in our ability to retest panel negative cases
because the testing was done under clinical auspices and
therefore no patient with initial negative results were retested
on a larger panel in this study. This means that the stated
diagnostic yields probably underestimate what could have been
achieved if everyone had been tested on the most up to date
panel. The average turnaround time for results was 21 working
days, less when no variants were seen (18 days) because Sanger
validation was not necessary, and slightly more when parental
segregation and new sample collection were necessary.
The pipeline used by Amplexa Genetics to establish pathogeni-
city of variants does indeed resemble other genetic testing NGS
models.11–13 The panels used were designed to cover all coding
exons and exon-intron boundaries of the included genes,
including an additional 10 bp of the introns. Sequences were
aligned to hg19 using the Torrent Suite (ThermoFisher) and SNPs
with a read depth ≥ 20 and variant allele frequency of ≥0.25 were
called using the Strand NGS software. Rare or low frequency
variants were evaluated in an internally developed pipeline.
Included in this evaluation were literature and database searches
like Human Gene Mutation Database (HGMD), Exome Aggregation
Table 1. Demographics of patients for gene panel testing
Age at seizure onset Syndrome Number Age at testing median years, (range)
Neonatal (0–1 mo) NEE 14 3.75 (0.2–16.9)
Benign neonatal 2 0.2 (0.2)
Infantile (2–24 mo) Infantile EE 19 7.5 (0.3–22.9)
FS/TLE spectrum 4 6.1 (1.3–18.3)
Infantile spasms 11 6.5 (0.5–12.2)
Childhood (>2 y) NFLE/SHE 6 13.7 (5.6–17.6)
Generalised (LGS-like) 9 15.1 (3.4–19.9)
Early-onset absence 4 7.45 (1.4–14.7)
Epilepsy-Aphasia spectrum 11 10.8 (7.3–17.2)
Familial focal epilepsy 8 10.45 (4.0–14.5)
Refractory focal epilepsy 8 9 (4.4–17.4)
Total 96 7.5 (0.2–22.9)
NEE neonatal epileptic encephalopathy (epilepsy with onset between birth and 3 months of age),
IEE infantile epileptic encephalopathy (epilepsy with onset between 4 and 12 months),
GEFS generalised epilepsy with febrile seizures (https://www.epilepsydiagnosis.org/syndrome/fbp-overview.html),
TLE temporal lobe epilepsy (https://www.epilepsydiagnosis.org/syndrome/other-familial-temporal-lobe-overview.html),
NFLE nocturnal frontal lobe epilepsy also known as SHE sleep-related hypermotor Epilepsy,37
LGS Lennox–Gastaut syndrome (https://www.epilepsydiagnosis.org/syndrome/lgs-overview.html)
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Consortium (ExAC) database, the Genome Aggregation Database
(gnomAD). Synonymous variants and variants in autosomal
dominant genes which had been observed more than three
times or in homo-/hemizygous state in the ExAC/gnomAD
database were excluded in severe epileptic encephalopathy (EE)
cases. All variants were submitted to prediction tools—predictions
on protein level were obtained from dbNSFP Functional Predic-
tions and Cores 3.0 database while the variants were submitted to
bioinfomatic software tools, e.g., NNSplice and ESEﬁnder for
predictions on transcriptional level. The ACMG guidelines were
applied to the resulting variants.11 Pathogenic variants are listed in
Table 2: SCN8A (n= 4) and SCN2A (n= 3) were the two most
commonly implicated genes. Two pathogenic variants were
observed in SCN1A but not in typical SCN1A-associated general-
ised epilepsy with febrile seizures or Dravet syndrome cases.
Variants of unknown signiﬁcance were detected in GABRA5,
SCN8A, CHRNB2, RYR3, HNRNPU, CACNA1A, SPTAN1, PIGA, KCNQ3,
SLC2A1, NPRL3 and CHRNA4 (Table 3).
Variant yield
The yield varied according to age of seizure onset—Table 4 shows
results by patient and, if a patient has several different variants
they are classiﬁed by their most 'serious' ranked variant
(pathogenic > VUS > benign). The 59 patients with at least one
variant (benign, VUS and pathogenic included) had a total of 54
benign variants amongst them (17 patients had more than one
benign variant and 6 had one or more benign variants plus a VUS
or pathogenic variant as well); 9 variants of unknown signiﬁcance;
and 20 pathogenic variants (one patient had two variants in two
different genes). 12 of the variants were Class 4 and 7 were class 5,
as per the ACMG guidelines.11 The diagnostic yield, deﬁned as the
percentage of cases “solved” by NGS panel testing was highest in
the neonatal onset epilepsies (63%), intermediate in the remaining
ﬁrst 2 years of life (21%), and lowest when onset was later (4%).
The diagnostic yield was 23% among drug resistant cases.
Clinicians attempted gene prediction (by informed guesses) in
33 cases, and were correct in ﬁve (15%): SCN1A, PCDH19, GRIN2A,
CDKL5, SCN2A.9
Impact
In 63% of cases with pathogenic variants, the results had an
immediate implication for treatment. Most involved ion channel
subunit genes such as SCN1A, SCN2A, SCN8A, KCNQ2, leading to
recommendations about Na+ blocking antiepileptic drugs in 10
cases. Two cases with acetyl-choline receptor subunit variants that
were suspected phenotype modiﬁers (CHRNA4, CHRNB2) were
offered experimental nicotine therapy.14 It should be noted that
the patient with the CHRNB2 VUS did not have his treatment
altered because of this VUS. However, as we suspected it to be a
phenotype modiﬁer, he was offered the chance to try experi-
mental nicotine therapy as an adjunctive treatment, to see if that
had any impact on his seizures. One-quarter of cases were entered
into a registry or research study. The families with pathogenic
variants were offered expert genetic counseling: in six cases (31%)
an additional affected relative was diagnosed.
Workshop and surveys
19 paediatricians and epilepsy nurses attended the workshop and
all offered feedback. 100% agreed that the workshop was
excellent and they were likely to change their practice going
forward. We received 10 survey responses from families (25%
response), and six from clinicians (40%). Both the outpatient and
molecular diagnostic components of the service were rated as
good or excellent (100%) by clinicians. Families also rated our
services highly and 100% would recommend to friends and family
(Table 5).
Investigational cost
We retrieved complete records for 16 neonatal epilepsy patients.
Total investigation costs ranged from £5094 to £15,622, average
£9362, with more than 75% of the costs allocated to neuroima-
ging and videoEEG-telemetry. In multiple linear regression, we
found statistically signiﬁcant and independent correlation only
between diagnostic delay and cost of previous genetic tests (p=
0.011).
Prior single gene testing among this sample included Fragile-X
(FMR1), Ataxia-Telengectasia (ATM), Niemann-Pick C (NPC1, NPC2),
spinal muscular atrophy (SMN1, SMN2), Prader-Willi syndrome
(15q11.2-q13), myotonic dystrophy (DMPK), ARX, atypical Rett
syndrome (CDKL5), and Glutaric aciduria Type 1 (GAT1). Because
both MRI and EEG can be performed for disease monitoring as
well as diagnosis, we excluded these and focused on the
remaining laboratory analyses performed on blood, urine and
cerebrospinal ﬂuid (CSF) samples. We found that two-thirds of
these costs (total average per patient: £2004) were made up of
array CGH and single gene tests, as well as metabolic investiga-
tions and invasive lumbar puncture. The delay between epilepsy
onset and diagnosis ranged from 83 days to 17 years (median 3.4
years). Consequently, we calculated that if all neonatal epilepsy
patients underwent NGS panel testing as part of their ﬁrst line
investigations, their theoretical total investigational costs would
have averaged £2838, which is £6524 less (70%) than the actual
average cost.
DISCUSSION
NGS panel testing in epilepsy is largely effective and useful, and
has particular strengths for early onset epilepsies. The high
diagnostic yield in the neonatal (63%) and infant (21%) onset
groups is unprecedented. We do not think there is any one answer
as to why the yield was so high, however only selecting the most
appropriate patients for testing and having a good panel design
are of course very important factors.
There is a signiﬁcant impact on treatment and risk counselling
for the majority of genetically diagnosed cases.2 Families put a
high value on exploring the implications of the results for their
child and family; and referring clinicians appreciated the quality of
clinical interpretation and rapid turnaround time.
The inputs required are substantial and complex: in our context,
they were based on an existing integrated tertiary and secondary
level regional epilepsy service, and relied on an educated referral
base to select appropriate cases, an expert multidisciplinary team
for interpreting variants with clinical features, and the skills of a
specialized genetic counselor to translate ﬁndings into tangible
beneﬁts for families.
There is also a potential for huge reduction in investigation
burden, cost and delay, taking into account the priorities of users
and referrers.
Utility and effectiveness
Diagnostic yield and clinical impact. Yields of 10–48.5% have
been reported from diagnostic NGS panels consisting of 36–265
target epilepsy genes,7,9,15–20 with a higher diagnostic yield in
children under 2 years at seizure onset. We found patients with
pathogenic variants in the most common epilepsy genes SCN8A
(n= 4), SCN2A (n= 3), SCN1A (n= 2), KCNQ2 (n= 2) and STXBP1,
GRIN2A, CHRNA4 (n= 1 each), accounting for 70% of all presumed
disease-causing variants (Table 2). In all living cases involving Na
or K channel mutations, recommendations or changes were made
to antiepileptic medications. 9% of cases were entered into a
clinical trial; 26% of cases were entered into a phenotype registry
or study awaiting future trials, and families were introduced to
online patient groups. Additionally, one quarter of patients had
another relative diagnosed following their diagnosis. The rapid
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turnaround time of 21 working days (14 days for urgent cases)
means interventions could be started in sufﬁcient time to
theoretically modify disease course or prevent complications,
although the evidence base for such therapies is yet to be
established.21 In addition, we found presumed pathogenic
variants in epilepsy genes that have not been well characterized
including HNRNPU, and the recessive PIGT (homozygous). 8 of the
20 pathogenic variants have previously been published7,8,15,22–32 a
further 3 are listed in ClinVar (Table 2); while 9 are novel.
Single vs parallel gene testing. The philosophy of parallel testing
or 'gene-ﬁrst', in patients where a genetic cause is suspected but
there is extensive genetic heterogeneity, is vindicated by
clinicians’ limited ability to predict results, and by some
remarkable surprises. Clinician prediction was not often attempted
and we suspect this is because of the extreme genetic
heterogeneity, pleiotropy, reduced penetrance and variable
expression in infantile onset epilepsies, these factors providing
the rationale for parallel gene testing.33,34 The cases in which
prediction was attempted reﬂect examples where there is better
known genotype-phenotype correlation. There are for example,
some more speciﬁc clinical features that are characteristic of one,
or a handful, of genes: clustering of febrile seizures (PCDH19);
temperature sensitivity (SCN1A); etc. We discuss two case
examples involving patients with pathogenic mutation in these
genes in the discussion section.
Still there were many surprises as evidenced by the poor
prediction rate. The full phenotypic spectra of many epilepsy
genes are currently being reported in the literature; as part of our
continuing clinician education for referring clinicians, we aim to
disseminate this new knowledge to ensure that patients are
accurately selected for genetic testing. The following three cases
deserve discussion because they demonstrate the strong clinical
foundation necessary for genetic testing in epilepsy.
The ﬁrst was a 7-year-old child with early-onset (3 years) drug-
resistant absence seizures preceded by multiple febrile seizures;
her mother noted the absences were sensitive to high tempera-
ture. Her father had drug-responsive juvenile onset absence
epilepsy. aCGH showed a paternally inherited 15q13.3 deletion,
which explained the familial susceptibility to absence seizures, but
not the daughter’s early age of onset, drug resistance, febrile
seizures or heat sensitivity. Gene panel testing then revealed a de
novo mutation in SCN1A, p.Arg1648His (Table 2).
The second had an onset of Lennox-Gastaut like symptoms in
the ﬁrst year of life, with severe learning difﬁculties including
developmental regression of language and motor function at the
age of 3. He had a pattern of nocturnal motor seizures clustering
over several days, repeating three times per month, and was drug-
resistant. NGS panel results showed pathogenic variants in
HNRNPU (de novo) and CHRNA4 (inherited); the former explaining
his overall phenotype, the second explaining his clustering
nocturnal motor seizures. A trial of transdermal nicotine sig-
niﬁcantly reduced his nocturnal motor seizures and improved his
daytime communication and functioning.14 Both this case and the
SCN1A case exemplify how 'second hits' can modify a seizure
phenotype and also act as a focus for therapeutic modulation.
The third case had severe clusters of infantile convulsions
continuing for 48–72 h and recurring every few months with
intercurrent febrile illness; at age 11 years he became seizure free
Table 4. Variant yield by age of onset and epilepsy syndrome
Patients with
Age at
seizure
onset
no variants only
benign
variants
VUS pathogenic
variants
Total Diagnostic
yield
0–1 m 1 3 2 10 16 63%
2–24 m 14 10 3 7 34 21%
IEE 5 7 3 4 19 21%
FS/TLE 2 0 0 2 4 50%
IS 7 3 0 1 11 a9%
>2 y 22 18 4 2 46 4%
NFLE/
SHE
4 2 0 0 6 0%
GGE 4 3 2 0 9 0%
EOABS 0 4 0 0 4 0%
ESES 5 5 0 1 11 9%
FFE 4 2 1 1 8 13%
DRE-
FOC
5 2 1 0 8 0%
Grand
total
37 31 9 19 96 20%
aone further case was subsequently solved through whole genome
research investigation
Table 5. Referring clinicians’ opinions and families’ views of the epilepsy genetics service
Clinicians’ opinions
Do you think that genetic testing.. Yes
..helped you to conﬁrm or reﬁne an existing or suspected clinical diagnosis? 83%
..has allowed a diagnosis to be made earlier than with clinical and EEG data alone? 83%
..saved your patient from additional investigations? 50%
..results altered your treatment and/or management approach? 67%
..results prevented the prescription of drugs that could have worsened the epilepsy? 17%
..was helpful in providing an explanation of the underlying disease for the family? 83%
Families views
Question Strongly/Agree
How helpful was genetic testing in giving you a cause for your child’s Epilepsy? 70%
Did the healthcare professionals give you enough opportunity to ask questions? 100%
Did the healthcare professionals explain things in a way you could understand? 100%
How helpful did you ﬁnd it to attend the specialist outpatient clinic? 100%
How likely are you to recommend our service to friends or family who need similar care? 100%
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on levetiracetam and now attends college. His clinical features
resembled the seizure phenotype described in Epilepsy with
Mental Retardation Limited to Females.35 NGS panel testing
surprisingly revealed a mosaic heterozygous mutation in PCDH19.
There are very few reported cases in males, and the genetic
mechanism remains obscure.36
In the older age group (seizure onset > 2 years), the diagnostic
yield was relatively low (4%). One reason is that far fewer genes
have been discovered in later onset epilepsies, and this should
prompt us towards more concerted efforts in collaborative gene
discovery, especially in the focal epilepsies. However, it is likely
that many of these later-onset epilepsies have a more complex
aetiology and so even when we discover some of the associated
genes, their impact on disease development will probably be
modest and show wide variability of penetrance and expression
amongst affected individuals.
Genes for autosomal dominant sleep-related hypermotor
epilepsy, although among the ﬁrst discovered (CHRNA4, CHRNB2,
CHRNA2, KCNT1, DEPDC5, CRH, PRIMA1) still only explain approxi-
mately 10% of cases.37 Unfortunately, none of our ﬁve tested
patients carried a causative mutation, suggesting that genetic
testing is not cost-effective in differentiating nocturnal motor
phenomena in adolescents. Only recently, new genes for familial
focal epilepsy (FFE) have been reported from the GATOR1 pathway
(DEPDC5, NPRL2, NPRL3) and these were missing from earlier
versions of the gene panel CHE-46, CHE-76, CHE-85). While we
speculate that some of our FFE patients might have tested
positive, we note the low (0.8–12%) current yield in sporadic and
FFE cases.38
We also noted the low yield for children with infantile or
epileptic spasms. Infantile spasms are aetiologically heteroge-
neous: tuberous sclerosis is the most common single cause,
followed by hypoxic-ischaemic injury, stroke and brain malforma-
tions, and 70% of cases have abnormal MR imaging.39 In a recent
study of 44 unsolved infantile seizures cases, 7% had a de novo
chromosomal rearrangement, and pathogenic mutations were
revealed by trio exome sequencing in 28% of the remainder,
suggesting that the diagnostic yield can be signiﬁcant in fully
investigated unsolved cases.40 Among our nine unsolved cases, a
complete imaging, cytogenetic and metabolic screen had only
been completed in one, suggesting room for better workup of
these cases prior to NGS panel testing.
Necessary inputs
Clinical interpretation. Variant interpretation is not always
straightforward, and requires close cooperation between mole-
cular geneticist, bioinformatician, neurologist and genetic coun-
sellor. We dealt with a large volume of benign (n= 54) or VUS (n
= 11), which represents a substantial burden for clinical inter-
pretation as well as a source of uncertainty for families. VUS arise
for a number of reasons, e.g., inadequate bioinformatic prediction,
lack of functional data, missing segregation, or incomplete
knowledge of genotype-phenotype correlation. In this scenario,
segregation information on a novel variant only contributes to
diagnostic certainty when there is conﬁdence about the bioinfor-
matic prediction and the associated epilepsy phenotype. If the
evidence is scant, then proving that the change is de novo, or
segregates with disease in an affected parent will, in reality, make
very little difference to the patient or family until further evidence
establishes the VUS as likely pathogenic, or benign. Without
expert interpretation, clinicians may be vulnerable to pitfalls such
as over-interpreting variants as mutations or vice-versa,41 and
wrongly assigning pathogenicity to heterozygous variants in
recessive conditions.
Clinician education and health structure. Clinicians who under-
stand the beneﬁts and limitations of the service are able to offer it
most effectively to the right patients. Our educational workshop
was very useful in this regard, and most referrals that we received
from workshop participants were appropriate and properly
worked up beforehand. Without this hierarchical structure, there
is the possibility of bypassing guidelines on investigation and
wasting resources. However, clinical education is an ongoing
process and continuing feedback on outcomes and beneﬁcial
impacts are probably necessary to sustain and grow referrals and
appropriate NGS requests.
Genetic counseling. Despite universal access to the internet,
many families have limited understanding of the principles of
human genetics and require clear and relevant information,
relayed in the context of their own situation before they can make
an informed decision about genetic testing. Genetic counseling is
the process of helping people understand and adapt to the
medical, psychological, and familial implications of genetic
contributions to disease.42 The genetic counselor is therefore
ideally placed to discuss with the family: facilitating adaptation to
their child’s condition, discussing the process and implications of
genetic testing, as well as promoting informed choices, for now
and in the future (e.g., family planning). A large proportion of
genetic epilepsies are as a result of de novo mutations, and so
cascade testing for the wider family is often not necessary.
However, as germline mosaicism is now thought to be more
common than it was originally,43 the possibility of prenatal testing
in any future pregnancies is always discussed.
Re-engineering services for precision medicine
Clinician and family feedback. Clinicians valued the new specialist
service, perceiving it helpful for diagnosis, management and
counseling, and 50% believed it had saved additional investiga-
tions. Referrals increased over the course of the study, indicating
an unmet need in the population. Families also found the
experience of genetic counseling and testing helpful, regardless of
whether their child’s case was solved or not. This feedback points
to the need for informed and unhurried discussion around genetic
testing, something that cannot be currently achieved in the
current constraints of a general neurology clinic.
Cost saving. Clinician perceptions of cost-saving are supported
by the analysis of neonatal epilepsy data, showing that investiga-
tion costs could be reduced by two-thirds by ordering an NGS
panel earlier in the pathway, which has been noted before.2,4,5
This might also reduce the median diagnostic delay from 3.43
years to 21 days and feasibly allow the early use of disease-
modifying drugs. However, true cost-savings are likely to be less
than the theoretical and would need to be calculated using a
prospective study design, preferably with a non-NGS tested
concurrent control group. Such calculations may need to be
repeated as technology evolves. Nevertheless, guideline revision
requires consensus and commitment from multiple organizational
stakeholders.
Limitations
While a prospective design has many advantages in terms of
selection bias, there are a couple of limitations of this study. First,
because our clinical pathway separates children with primary
epilepsy from all children with early-onset seizures, and requires a
routine workup to exclude lesional and some metabolic causes as
well as excluding single gene testing for SCN1A and SLC2A1, the
results may not be generalizable to other health care contexts.
Second, our diagnostic yield concealed some variability because
of the evolution of the gene panel over the period of study,
reﬂecting the fast pace of gene discovery—this might have led to
some under-diagnosis of patients using earlier panels.
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CONCLUSION
NGS-based genetic testing has high clinical utility in children with
epilepsy onset before 2 years or in drug-resistant or familial cases.
The impacts are numerous and range from treatment change to
risk counseling, and potential recruitment to clinical trials as new
experimental therapies become available. A successful service
requires strong engagement from secondary health care provi-
ders, an existing framework for specialist referral and investiga-
tion, substantial collaboration between clinicians and scientists for
variant interpretation, as well as expertise in genetic counseling
and ﬂexibility in communicating with and meeting the evolving
needs of families. To make the best of any innovation in medicine,
health care organizations need to be open to change and
reconﬁguration of resources to beneﬁt patients and their families.
METHODS
Ethics
(a) Methods were performed in accordance with relevant regulations and
guidelines and (b) methods were approved by The Great Ormond Street
Hospital/Institute of Child Health Research Ethics Committee (reference
number: 09/H0713/76).
Population
We collected prospective data related to genetic testing on 96 patients
referred to the King’s Health Partners epilepsy genetics service for
molecular diagnostic testing, between November 2014 and September
2016. The service is provided to the southeast region of England, a
population of approximately 3.5 million including the south-east of
London. The region includes two teaching hospitals with tertiary paediatric
neurology departments (King’s College Hospital NHS Trust and Evelina
London Children’s Hospital) and eleven district general hospitals in which
there is a general paediatrician with a special interest in epilepsy. Medical
services are state-run and organized through a regional clinical network
with common management guidelines for epilepsy.44 Patients are seen
ﬁrst at their district general hospital before being referred, if appropriate,
for a tertiary specialist opinion either at one of the two tertiary centres or in
a regional specialist epilepsy clinic.
The epilepsy genetics service comprises two components: a specialist
clinic run by a paediatric epileptologist with a research interest in genetics
(DKP), a genetic counselor (SO) and clinical fellow (ST, RR); and a molecular
genetic diagnostic service using an NGS epilepsy panel (LHGL, QH, HAD),
with clinical interpretation by the whole team.
Pathway
In the absence of consensus guidelines, we considered patients suitable for
genetic testing with either early-onset (<2 years) epilepsy, treatment
resistant epilepsy of unknown cause, or familial epilepsy where the genetic
cause was unknown. Two of our patients sadly died during the testing
process. As a rule, we only considered patients with epilepsy as their
primary diagnosis, rather than patients with intellectual disability (ID) or
autism (ASD) who had seizures as part of their phenotype. This is because
our service is part of the epilepsy service, whereas patients with primary ID
or ASD who also have seizures do not usually use our pathway, unless they
have a relevant family history. Patients followed one of three pathways for
genetic testing: either being seen (i) in the specialist epilepsy genetic clinic,
as above (n= 40); (ii) by a paediatric neurologist (n= 7) or paediatric
epileptologist (n= 37) at one of the two tertiary centres; or (iii) seen by a
general paediatrician (n= 12) with a special interest in epilepsy at a district
general hospital, with referrals made in discussion with their linked
paediatric epileptologist. Patients were recommended to have completed
routine aetiological investigations as per regional guidelines (EEG, MRI,
metabolic as necessary), and the clinician was asked to complete a
proforma summarizing the electroclinical phenotype, epilepsy syndrome,
age at seizure onset, drug response, results of previous investigations, and
clinical prediction of candidate gene. We collected aCGH data in cases
where it had been performed. Children with suspected typical Dravet
Syndrome (OMIM 607208) or Glut-1 Deﬁciency syndromes (OMIM 606777)
undergo single gene testing and were not included here; patients with
brain malformations are tested on a separate gene panel and also not
discussed here.
At the outpatient visit, we spent approximately 1 h with each new
patient. The paediatric epileptologist and genetic counsellor took a
detailed clinical and genetic history and performed a neurological
examination on the affected child. Patients were operationally categorized
into broad epilepsy syndromes (Table 1) because many did not ﬁt into the
International League Against Epilepsy classiﬁcation of epilepsy syn-
dromes.45 The genetic counselor then discussed the possibility of NGS
panel testing, and if the family were interested, proceeded to explain: the
process; beneﬁts and limitations; potential outcomes and what they might
mean; discussed any issues of concern that might arise around results,
obtained written informed consent (using the appended consent form)
prior to the start of this study, and planned for follow-up.
Education
We held a half-day educational workshop aimed at regional paediatricians
and epilepsy nurses, to discuss which patients were suitable for testing,
which test to choose and how to obtain informed consent. We designed
the educational workshops along evidence-based lines for effective
learning, using case-based simulations in small groups.46–48 After the
workshop, attendees gave anonymous feedback indicating that 100% of
them were 'likely' or 'very likely' to change their practice. We circulated
proposed guidelines for genetic testing to the group which were agreed in
consensus. Following this, in actual practice we have seen the number of
referrals increase and that most referrals meet our published guidelines.
Furthermore, the number of new referrers has increased and as we provide
email feedback to every referrer, appropriateness is also improving
amongst new referrers. Additionally, we posted separate information for
clinicians and families on our website www.childhood-epilepsy.org.
Gene panel
We used the Amplexa Genetics epilepsy gene panel CHE-46 (46 epilepsy
genes) at the start of the service,7 which was updated to CHE-76, CHE-85
and CHE-102 during the study period in light of new gene discoveries (by
DKP, RM, HAD), (Table 6). To identify putative disease-causing variants, we
performed targeted NGS of 46–102 epilepsy genes in four successive
panels (January 2014—January 2016). The criteria for including a gene on
the panel were that it should have been reported more than once in
patients with monogenic epilepsies. The genes included on the CHE-46
panel were: ALDH7A1, ALG13, ARHGEF9, CACNA1A, CDKL5, CHD2, CPA6,
DEPDC5, DNM1, GABRA1, GABBR1, GABBR2, GABRB3, GABRD, GABRG2,
GNAO1, GRIN1, GRIN2A, GRIN2B, HCN1, HDAC4, HNRNPU, IQSEQ2, KCNA2,
KCNQ2, KCNQ3, KCNT1, KCTD7, LGI1, MBD5, PCDH19, PLCB1, PNPO, PRRT2,
SCN1A, SCN1B, SCN2A, SCN8A, SLC25A22, SLC2A1, SLC35A3, SPTAN1, STX1B,
STXBP1, SYNGAP1, and TBC1D24; additionally for CHE-76: ADSL, ATP1A2,
ATP1A3, ATRX, CHRNA2, CHRNA4, CHRNB2, GABRA5, GAMT, GATM, MECP2,
MEF2C, MTOR, PIGA, PIK3AP1, PNKP, POLG, PURA, RYR3, SLC25A2, SLC6A1,
SLC6A8, SLC9A6, SMARCA2, TCF4, UBE3A; and additionally for CHE-85:
CLCN2, CNKRS2, FASN, FOXG1, HDAC4, HNRNPU, HUWE1, KCNH5, KCTD7,
MBD5, PIGO, PIGT, RELN, SIK1, SLC13A5, SLC35A2, SLC35A3, SLC6A8, SLC9A6,
ZDHHC9; and for CHE-102: CACNB4, CUX2, EEF1A2, GRIN2D, KANK1, KCNB1,
KCNMA1, KIAA2022, NPRL2, NPRL3, PIK3R2, ST3GAL3, SZT2, WWOX. aCGH,
where performed, was conducted using an oligonucleotide array with
~60,000 probes across the genome. Paternity testing was not performed.
Sample preparation
Genomic DNA was extracted from blood using standard methods. For the
CHE-45, panel libraries were prepared from 15 ng of template DNA using
the Ion AmpliSeq library 2.0 kit and custom primers following the
manufacturer’s instructions (ThermoFisher Scientiﬁc).7 The CHE-76, CHE-85
and CHE-102 panel libraries were prepared from 1000 ng template DNA,
Agilent SureSelect target enrichment (Agilent technologies) and KAPA
library preparation kit (KAPA Biosystems) following manufacturer’s
instructions. The library DNA was clonally ampliﬁed onto the Ion Spheres
Particles (ISPs) by emulsion PCR using an Ion OneTouch 2 system and the
Ion PGM Template OT2 200 kit (ThermoFisher Scientiﬁc). ISPs were
sequenced on an Ion PGM sequencer using an Ion 314, Ion 316 or Ion 318
chip and the Ion PGM 200 Sequencing kit as per the manufacturer’s
instructions (ThermoFisher Scientiﬁc).
Bioinformatics
Sequences were mapped to hg19 in the Torrent suite software (Thermo-
Fisher Scientiﬁc) and variant calling was achieved in the Strand NGS
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software (Avadis) with a minimum of 20-fold read depth. Common SNPs
with an allele frequency ≥ 2% and SNPs observed in more than 2 samples
for each analyzed sample batch were ﬁltered out. Genetic nonsynon-
ymous/splice site variants were evaluated through database searches:
dbSNP, Exome Variant Server, the Exome Aggregation Consortium
database (ExAC), the Genome Aggregation Database (gnomAD) and
HGMD Professional. Missense variants were also submitted to prediction
softwares such as SIFT and PolyPhen-2, while splice site variants were
evaluated by NNSPlice and Splicesite ﬁnder. Variants analyzed under a
dominant inheritance model that were observed more than 10 times in
ExAC were considered too common as monogenic causes. Potentially
pathogenic variants were validated through conventional Sanger sequen-
cing, and, if possible, parents were included for segregation analysis when
indicated.
Criteria for assessing pathogenicity of rare variants
We share the brief clinical summary of the patient with the laboratory to
aid genotype-phenotype correlation; subsequently we interpret the gene
panel report in detailed clinical context at a monthly multidisciplinary
meeting including epileptologists (EH, REW, KL, DKP), a clinical neurophy-
siologist (SG) and genetic counselor (SO). We also consulted bioinformatics
databases, patient registries, expert colleagues and published literature.
Laboratory reported variants categorized by the ACMG system11 were then
(re-)classiﬁed by us as either benign variants, VUS, or pathogenic variants
for the purposes of genetic counselling. For predicted possibly damaging
variants where segregation analysis could be performed, we required the
variant to meet one of the following criteria to constitute a likely
pathogenic variant: de novo in early-onset severe epilepsy syndromes,
segregation with the disorder, inheritance from an unaffected parent but
previously reported in other families with the same phenotype and
incomplete penetrance, or adherence to a recessive X-linked or parent-of-
origin mode of inheritance.
Result feedback
We offered either a telephone or face-to-face consultation to the family,
followed up with a written summary of the discussions in a letter.
Opinion survey
We solicited the views of all 40 families through an anonymous 16-item
questionnaire available as paper copy or web version (www.surveymonkey.
com). The questionnaire covered three main topics of quality, impact and
perceived value, and was formulated with the assistance of the Head of
Patient Experience at one of the tertiary centres. We also sent an email link
to a 10-item anonymous (www.surveymonkey.com) questionnaire to all 15
clinicians who had referred patients to the epilepsy genetics service
(questions were adapted from a longer survey used in the evaluation of
SCN1A testing6).
Investigational cost
We searched electronic patient records to generate a list and timing of all
investigations ordered in the neonatal epilepsy group; then matched these
against 2017 hospital tariffs, separating them into categories of
neuroimaging; EEG; routine blood tests; metabolic investigations of blood,
urine and CSF; tissue biopsy; array CGH and karyotype; single gene tests;
and NGS panel. We assessed the independent association of imaging, EEG,
metabolic and genetic tests with diagnostic delay in days using multiple
linear regression.
Table 6. Gene panels used in this study, categorized by gene function
Ion transport Neuro-transmitter related Gene expression Scaffolding and trafﬁcking Intracellular signalling Other functions
ATP1A2 CHRNA2 ARX CNKSR2 DEPDC5 ADSL
ATP1A3 CHRNA4 ATRX DNM1 GNAO1 ALDH7A1
CACNA1A CHRNB2 CHD2 IQSEC2 MTOR ALG13
CACNA1H GABBR1 CUX2 KANK1 NPRL2 ARHGEF9
CACNB4 GABBR2 EEF1A2 KIAA2022 NPRL3 CDKL5
CLCN2a GABRA1 FOXG1 PCDH19 PIK3R2 CPA6
HCN1 GABRA5 HDAC4 PIGA PLCB1 FASN
KCNA2 GABRB3 HNRNPU PIGO RYR3a GAMT
KCNB1 GABRD HUWE1 PIGT SIK1 GATM
KCND2 GABRG2 MBD5a RELN PIK3AP1
KCNH5 GRIN1 MECP2 SPTAN1 PNKP
KCNH8 GRIN2A MEF2C STX1B PNPO
KCNMA1 GRIN2B PURA STXBP1 POLG
KCNQ2 GRIN2D SMARCA2 TBC1D24 ST3GAL3
KCNQ3 NRXN1 TCF4 SLC13A5
KCNQ5 PRRT2 ZDHHC9 SLC2A1
KCNT1 SLC1A2 SLC35A2
KCTD7a SLC25A22 SLC35A3
LGI1 SYNGAP1 SLC6A8
SCN1A SZT2
SCN1B UBE3A
SCN2A WWOX
SCN8A
SLC12A5
SLC6A1
SLC9A6
CHE-45, CHE-76 additions, CHE-85 additions, CHE-102 additions
aRemoved from CHE-102
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Data availability
All supporting data can be found as presented in this paper.
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